⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14597372 | 1.00 | — | — | |
| SCHEMBL11890818 | 1.00 | — | — | |
| SCHEMBL13167831 | 0.81 | — | — | |
| SCHEMBL2091418 | 0.81 | — | — | |
| SCHEMBL19369809 | 0.80 | FDPS (0.32) | — | |
| SCHEMBL14628087 | 0.77 | — | — | |
| SCHEMBL14628083 | 0.77 | — | — | |
| SCHEMBL13481202 | 0.76 | ACE (0.40) | — | |
| SCHEMBL13185695 | 0.74 | ACE (0.36) | — | |
| SCHEMBL12788536 | 0.72 | ACE (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11072634-B2 | Inhibitors of transglutaminases | ZEDIRA GMBH (DE) | 2021-07-27 | — | — | US | disclosed |
| US-20210147478-A1 | INHIBITORS OF BLOOD COAGULATION FACTOR XIII | ZEDIRA GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| US-9217022-B2 | GLP-1 receptor agonist compounds having stabilized regions | ASTRAZENECA PHARMACEUTICALS LP (US) | 2015-12-22 | — | — | US | disclosed |
| US-20140162943-A1 | N-TERMINUS CONFORMATIONALLY CONSTRAINED GLP-1 RECEPTOR AGONIST COMPOUNDS | ASTRAZENECA PHARMACEUTICALS, LP (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140162943-A1 | N-TERMINUS CONFORMATIONALLY CONSTRAINED GLP-1 RECEPTOR AGONIST COMPOUNDS | ASTRAZENECA PHARMACEUTICALS, LP (US) | 2014-06-12 | — | — | US | disclosed |
| US-8642544-B2 | N-terminus conformationally constrained GLP-1 receptor agonist compounds | AMYLIN PHARMACEUTICALS, LLC (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642544-B2 | N-terminus conformationally constrained GLP-1 receptor agonist compounds | AMYLIN PHARMACEUTICALS, LLC (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130184203-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS HAVING STABILIZED REGIONS | ASTRAZENECA PHARMACEUTICALS LP (US) | 2013-07-18 | — | — | US | disclosed |
| US-20120046222-A1 | N-TERMINUS CONFORMATIONALLY CONSTRAINED GLP-1 RECEPTOR AGONIST COMPOUNDS | AMYLIN PHARMACEUTICALS, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-7238671-B2 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238671-B2 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238670-B2 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238670-B2 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-20070004642-A1 | Oxadiazole derivatives and drugs containing these derivatives as the active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2007-01-04 | — | — | US | disclosed |
| WO-2004094461-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2003033671-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-24 | — | — | WO | disclosed |